BioSpace News Archive

Nearly three-quarters (74%) of Americans who contract the flu call out sick from work or school and more than a third (35%) missed more than a week last year, reducing productivity all over the country.

Convergent Dental, Inc., developer of Solea®, the industry-leading 9.3 µm CO2 all-tissue dental laser, has chosen Wayne Craig as their new National VP of Sales.

Progenity, Inc. announced today that the company will be participating in the Piper Jaffray 31st Annual Healthcare Conference in New York, December 3-5.

Cerebras Systems, a company dedicated to accelerating Artificial Intelligence (AI) compute, today unveiled its CS-1 system, the world’s fastest AI computer. With every component optimized for AI work, the CS-1 delivers more compute performance at less space and less power than any other system.

BioVentrix, Inc. announced that the U.S. Food and Drug Administration has granted the company Breakthrough Device Designation status for its Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced the appointment of Brad Smith to its Board of Directors

Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery, today announces the broadcast of its audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community.

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Canada has granted priority review status for the New Drug Submission (NDS) for Gliolan® (5-aminolevulinic acid hydrochloride).

QCCA Network of 20 Oncology Practices to Integrate Population Health Analytics Solutions to Achieve Clinical and Financial Objectives Under Value-Based Care

CRH Medical Corporation (the “Company”) (TSX: CRH) (NYSE MKT: CRHM), announces that it has exercised its option, effective November 1, 2019, completing an accretive transaction whereby the Company now holds a 51% interest in a gastroenterology (“GI”) anesthesia practice in Winston-Salem, North Carolina (“Triad Sedation”)